Avicanna Inc. reported a positive adjusted EBITDA of $0.22 million for Q3 2026, improving by $1.01 million year-over-year and narrowing its operating loss by 80% to $0.27 million. Revenue reached $5.73 million, marking a 2% increase from Q2 2026 despite challenges from Veterans Affairs Canada reimbursement changes earlier in the year. The company expanded its proprietary product sales in Canada by 16% year-over-year and launched the QUIX™ Rapid Onset product line with 10 SKUs, enhancing its market position. Avicanna also strengthened its financial position with improved working capital and a $2 million financing, positioning itself for domestic scaling and international expansion.
Avicanna's Q3 2026 financial update provides context for health-sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 19:11 WIB: Out of 150 priced US health-sector stocks, 91 rose and 53 fell. Guardant Health Inc. (GH) rose 2.40% to USD 158.50 with a typical hold time of 10 days. Nuwellis Inc (NUWE) fell 2.35% to USD 5.66 with 100% sell order activity and a 32-day hold time. AdaptHealth Corp (AHCO) dropped 2.31% to USD 7.62 with 100% sell order activity and a 21-day hold time.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
